FibroGen Management
Management criteria checks 2/4
FibroGen's CEO is Thane Wettig, appointed in Jul 2023, has a tenure of less than a year. total yearly compensation is $3.64M, comprised of 15.7% salary and 84.3% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth MX$3.68M. The average tenure of the management team and the board of directors is 2.9 years and 5.3 years respectively.
Key information
Thane Wettig
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 15.7% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 2.9yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$240m |
| Dec 31 2023 | US$4m | US$573k | -US$284m |
| Sep 30 2023 | n/a | n/a | -US$294m |
| Jun 30 2023 | n/a | n/a | -US$322m |
| Mar 31 2023 | n/a | n/a | -US$307m |
| Dec 31 2022 | US$3m | US$535k | -US$294m |
| Sep 30 2022 | n/a | n/a | -US$362m |
| Jun 30 2022 | n/a | n/a | -US$220m |
| Mar 31 2022 | n/a | n/a | -US$281m |
| Dec 31 2021 | US$3m | US$510k | -US$290m |
| Sep 30 2021 | n/a | n/a | -US$215m |
| Jun 30 2021 | n/a | n/a | -US$231m |
| Mar 31 2021 | n/a | n/a | -US$183m |
| Dec 31 2020 | US$4m | US$263k | -US$189m |
Compensation vs Market: Thane's total compensation ($USD3.64M) is above average for companies of similar size in the MX market ($USD197.96K).
Compensation vs Earnings: Thane's compensation has increased whilst the company is unprofitable.
CEO
Thane Wettig (59 yo)
less than a year
Tenure
US$3,640,829
Compensation
Mr. Thane Wettig serves as Director of FibroGen, Inc. since October 2, 2023. He serves as Chief Executive Officer at FibroGen, Inc. since October 2, 2023 and served as Interim Chief Executive Officer since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.64m | 0.19% $ 3.7m | |
| Senior VP & CFO | 2.8yrs | US$3.09m | 0.065% $ 1.2m | |
| Senior Vice President of China Operations | 17.4yrs | US$3.11m | 0.32% $ 6.2m | |
| Founder | 29.4yrs | no data | no data | |
| Chief Scientific Officer | 2.9yrs | no data | no data | |
| Vice President of Corporate FP&A and Investor Relations | no data | no data | no data | |
| Chief Legal Officer | 8.2yrs | no data | no data | |
| Chief People Officer | 3.1yrs | no data | no data | |
| Chief Business Officer | 3.6yrs | no data | no data | |
| Senior Vice President of Pharmaceutical Development | 2.4yrs | no data | no data | |
| Senior VP of Regulatory | less than a year | no data | no data | |
| Senior VP & Chief Medical Officer | less than a year | no data | 0.083% $ 1.6m |
2.9yrs
Average Tenure
56yo
Average Age
Experienced Management: FGEN *'s management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.64m | 0.19% $ 3.7m | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5yrs | US$388.03k | 0.021% $ 411.9k | |
| Independent Director | 8.7yrs | US$385.53k | 0.026% $ 496.5k | |
| Independent Chairman of the Board | 14.2yrs | US$499.58k | 0.082% $ 1.6m | |
| Independent Director | 6.8yrs | US$383.03k | 0.037% $ 716.7k | |
| Independent Director | 5.5yrs | US$375.53k | 0.023% $ 448.7k | |
| Independent Director | 3.8yrs | US$392.55k | 0.021% $ 395.2k | |
| Independent Director | 3.8yrs | US$373.03k | 0.020% $ 380.0k |
5.3yrs
Average Tenure
63yo
Average Age
Experienced Board: FGEN *'s board of directors are considered experienced (5.3 years average tenure).